Novo asked the court to permanently stop Lilly from running the "deceptive" ads and require the drugmaker to issue corrective advertising.

Novo Nordisk CEO defended the company's decision to sue rival Eli Lilly over its weight-loss drug advertising.

Novo alleges Lilly compared the highest approved doses of its medicines with lower doses of Novo’s Wegovy and Ozempic while omitting newer, higher-dose versions that Novo says deliver greater weight ...

Two of the world's biggest pharmaceutical companies are headed to court after Novo Nordisk, the maker of Ozempic and a pioneer in diabetes and obesity treatments, sued rival Eli Lilly on Tuesday, ...

Novo is seeking to force Lilly to pull the disputed ads and run corrective ones as the companies compete for dominance in the booming obesity drug market.

Novo Nordisk claims Eli Lilly aired misleading ads comparing the pharma companies' respective weight-loss drugs, Wegovy and Zepbound.

This wave of Hatch-Waxman cases comes as patent disputes involving GLP-1 receptor agonists, especially Novo Nordisk's Ozempic ...

Novo Nordisk sued Eli Lilly in New Jersey, alleging deceptive ads comparing high-dose Zepbound to lower doses of Wegovy.

Novo Nordisk (NYSE:NVO) has filed a federal lawsuit against Eli Lilly, alleging that its rival’s advertising campaigns for blockbuster GLP-1 obesity and diabetes drugs mislead consumers about the ...